EU/3/02/130: Orphan designation for the treatment of gastric cancer

G17(9) gastrin-Diphtheria Toxoid Conjugate

Table of contents


On 28 January 2003, orphan designation (EU/3/02/130) was granted by the European Commission to Orion Clinical Services Limited, United Kingdom, for G17(9) gastrin-diphtheria toxoid conjugate for the treatment of gastric cancer.
The sponsorship was transferred to Kendle International Ltd, United Kingdom, in December 2004 and subsequently to Cato Europe GmbH, Germany, in March 2009.

Key facts

Active substance
G17(9) gastrin-Diphtheria Toxoid Conjugate
Intended use
Treatment of gastric cancer
Orphan designation status
EU designation number
Date of designation
Cato Europe GmbH
Hertzstrasse 7
50859 Cologne
Tel. +49 2234 37944 10
Fax +49 2234 37944 25

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating